Biopharma Market Access · near ·

EU joint clinical assessments give health economics software vendors a direct pitch to pharmaceutical market access chiefs

Enforcement of the EU Health Technology Assessment Regulation is forcing biopharma manufacturers to produce synchronised comparative clinical efficacy dossiers across member states. Meanwhile, traditional commercialisation timelines are collapsing as drug launches require simultaneous alignment between US pricing strategy and European clinical assessments. Drug sponsors unable to produce automated, real-time health economic models face multi-year commercial delays and fragmented reimbursement access.

Part of the Healthcare & Life Sciences Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.

Related opportunities